Stay up to date with news and events
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
December 9, 2022
The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment…
uniQure gets the green light to resume testing HD gene therapy
November 5, 2022
In August 2022, uniQure announced a pause in new recruitment for their trial of AMT-130, an HD gene therapy delivered via brain surgery. The decision…
Update on the PTC Therapeutics PIVOT-HD Trial
November 4, 2022
Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of…
Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
October 2, 2022
In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their…
Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
September 10, 2022
A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made…